THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN) Wednesday announced a positive
results for its Phase 3 clinical trial evaluating the efficacy and safety of
Uplizna for the treatment of Immunoglobulin G4-related disease or IgG4-RD.

The randomized, double-blind, multicenter, placebo-controlled trial met its
primary endpoint, showing a statistically significant 87 percent reduction in
the risk of IgG4-RD flare compared to placebo.

IgG4-RD is a chronic, immune-mediated disease and Uplizna is currently approved
for Neuromyelitis Optica Spectrum Disorder.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX